This week’s Rare Diseases update highlights clinical progress across endocrine and hematologic disorders, long-term outcomes in pediatric and genetic conditions, regulatory incentive activity, and emerging pipeline developments.
In Today’s Newsletter
Dive deeper
🧬 Asedebart Phase 2 Cushing’s disease data [1] [Denmark/US • 14 Jun 2026]
https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-phase-ii-asedebart-data-in-cushing-s-disease-at-endo-2026,c4362170
Context: Lundbeck presented preliminary Phase 2 Part A data for asedebart (Lu AG13909), an anti-ACTH monoclonal antibody, at ENDO 2026.
Key point: UFC normalization occurred in 7 of 8 evaluable adults completing individualized IV dose titration.
Implication: May influence prescriber choice and payer reviews pending full data.
🩸 IMAAVY Phase 2/3 wAIHA results [2] [EU • 11 Jun 2026]
https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies
Context: Johnson & Johnson reported Phase 2/3 ENERGY data for IMAAVY (nipocalimab-aahu) in warm autoimmune hemolytic anemia.
Key point: The 30 mg/kg group achieved statistically significant durable hemoglobin response versus placebo, with mean hemoglobin improvement by Week 1.
Implication: May influence prescriber choice and payer reviews pending full data.
🍽️ VYKAT XR long-term PWS data [3] [US • 15 Jun 2026]
https://neurocrine.gcs-web.com/news-releases/news-release-details/soleno-therapeutics-presents-new-vykatr-xr-diazoxide-choline
Context: Soleno Therapeutics, a Neurocrine company, presented VYKAT XR (diazoxide choline) data at ENDO 2026 in Prader-Willi syndrome.
Key point: Participants resuming VYKAT XR after randomized withdrawal showed hyperphagia and behavioral improvements by Week 13, continuing through two years.
Implication: May influence prescriber choice and payer reviews pending full data.
📏 CRENESSITY pediatric CAH growth data [4] [US • 15 Jun 2026]
https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-presents-new-two-year-crenessityr-2
Context: Neurocrine reported two-year CAHtalyst Pediatric data for CRENESSITY (crinecerfont) in classic congenital adrenal hyperplasia.
Key point: Children with advanced bone age at baseline showed slowed bone age progression and improved predicted adult height after two years.
Implication: May influence prescriber choice and payer reviews pending full data.
🩹 SkinJect RPDD request in Gorlin syndrome [5] [US • 15 Jun 2026]
https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/medicus-pharma-announces-us-food-and-drug-administration-fda-submission-of-rare-pediatric-disease-designation-request-for-skinject-in-gorlin-syndrome/2365512
Context: Medicus Pharma submitted an FDA Rare Pediatric Disease Designation request for SkinJect in Gorlin syndrome.
Key point: SkinJect is an investigational doxorubicin microneedle array patch intended for lesion-directed basal cell carcinoma treatment.
Implication: Introduces competition that may affect pricing and formulary access.
🧠 DDC-02 preclinical neurodevelopmental data [6] [US • 11 Jun 2026]
https://www.biospace.com/press-releases/jw-pharmaceutical-presents-preclinical-results-and-global-development-strategy-for-ddc-02-a-novel-therapeutic-candidate-for-rare-neurodevelopmental-disorders
Context: JW Pharmaceutical presented preclinical DDC-02 data at WODC USA 2026 in rare neurodevelopmental disorder models.
Key point: DDC-02 restored cognitive and behavioral deficits in animal models of Pitt-Hopkins syndrome, Fragile X syndrome, and Rett syndrome.
Implication: Signals pipeline investment and modality expansion.
🫁 PAPZIMEOS orphan drug exclusivity in RRP [7] [US • 15 Jun 2026]
https://www.biospace.com/press-releases/precigen-gains-advantage-as-papzimeos-granted-orphan-drug-exclusivity-by-fda-long-term-data-from-clinical-study-encouraging
Context: Precigen said FDA granted orphan drug exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in recurrent respiratory papillomatosis.
Key point: Exclusivity extends market protection through August 2032; long-term data showed durable complete responses in responders.
Implication: Introduces competition that may affect pricing and formulary access.
💵 Rocket closes PRV sale [8] [US • 12 Jun 2026]
https://www.businesswire.com/news/home/20260612407717/en/Rocket-Pharmaceuticals-Announces-Closing-of-Sale-of-Rare-Pediatric-Disease-Priority-Review-Voucher-for-%24180-Million
Context: Rocket Pharmaceuticals closed the sale of a Rare Pediatric Disease Priority Review Voucher linked to KRESLADI approval.
Key point: The sale generated $180 million in gross proceeds and increased pro forma cash, equivalents, and investments to about $322.6 million.
Implication: Signals pipeline investment and modality expansion.
Why it matters
- Rare disease endocrine data dominated ENDO 2026, with Cushing’s disease, Prader-Willi syndrome, and congenital adrenal hyperplasia updates.
- FDA incentive pathways remain central, including Rare Pediatric Disease Designation, orphan drug exclusivity, and PRV monetization.
- Long-term follow-up is increasingly important, especially for pediatric growth, surgical burden, and chronic rare disease management.
- Several programs target disease burden beyond core biomarkers, including behavior, fatigue, surgery frequency, caregiver outlook, and treatment logistics.
📚 View the full Rare Disease archive on our research hub page
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
🎯 Catch up on the Top Rare Disease news from the past two weeks, curated by the LucidQuest team.
FAQ
What is asedebart from Lundbeck?
Asedebart (Lu AG13909) is an investigational anti-ACTH monoclonal antibody for Cushing’s disease. Lundbeck reported UFC normalization in most evaluable Phase 2 Part A patients. [1]
What did Johnson & Johnson report for IMAAVY in wAIHA?
IMAAVY (nipocalimab-aahu) showed a statistically significant durable hemoglobin response in the 30 mg/kg arm of the Phase 2/3 ENERGY study. [2]
What does VYKAT XR treat in this dataset?
VYKAT XR (diazoxide choline) is discussed for hyperphagia in Prader-Willi syndrome. New data showed durable hyperphagia and behavioral improvements after treatment resumption. [3]
What was the CRENESSITY pediatric update?
CRENESSITY (crinecerfont) two-year CAHtalyst Pediatric data showed slowed bone age progression and improved predicted adult height in children with advanced bone age at baseline. [4]
What is SkinJect in Gorlin syndrome?
SkinJect is Medicus Pharma’s investigational doxorubicin-containing microneedle array patch for basal cell carcinoma lesions in Gorlin syndrome. The company submitted an FDA RPDD request. [5]
Why does Rocket’s PRV sale matter?
Rocket Pharmaceuticals closed a $180 million gross-proceeds sale of its Rare Pediatric Disease PRV, increasing pro forma cash resources and extending expected funding into Q2 2028. [8]
Entities / Keywords
Lundbeck, H. Lundbeck A/S, asedebart, Lu AG13909, anti-ACTH monoclonal antibody, Cushing’s disease, urinary free cortisol, UFC
Johnson & Johnson, J&J, IMAAVY, nipocalimab-aahu, wAIHA, warm autoimmune hemolytic anemia, ENERGY study
Soleno Therapeutics, Neurocrine Biosciences, VYKAT XR, diazoxide choline, DCCR, Prader-Willi syndrome, PWS, hyperphagia
Neurocrine Biosciences, CRENESSITY, crinecerfont, CAHtalyst Pediatric, classic congenital adrenal hyperplasia, CAH
Medicus Pharma, SkinJect, doxorubicin microneedle array, D-MNA, Gorlin syndrome, nevoid basal cell carcinoma syndrome
JW Pharmaceutical, DDC-02, Pitt-Hopkins syndrome, Fragile X syndrome, Rett syndrome, rare neurodevelopmental disorders
Precigen, PAPZIMEOS, zopapogene imadenovec-drba, recurrent respiratory papillomatosis, RRP, orphan drug exclusivity
Rocket Pharmaceuticals, KRESLADI, leukocyte adhesion deficiency-I, LAD-I, Rare Pediatric Disease PRV
References
- https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-phase-ii-asedebart-data-in-cushing-s-disease-at-endo-2026,c4362170
- https://www.jnj.com/media-center/press-releases/imaavy-nipocalimab-aahu-demonstrates-durable-hemoglobin-response-and-rapid-onset-of-effect-in-pivotal-phase-2-3-study-in-warm-autoimmune-hemolytic-anemia-waiha-an-autoantibody-driven-disease-with-no-fda-approved-therapies
- https://neurocrine.gcs-web.com/news-releases/news-release-details/soleno-therapeutics-presents-new-vykatr-xr-diazoxide-choline
- https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-presents-new-two-year-crenessityr-2
- https://www.manilatimes.net/2026/06/15/tmt-newswire/globenewswire/medicus-pharma-announces-us-food-and-drug-administration-fda-submission-of-rare-pediatric-disease-designation-request-for-skinject-in-gorlin-syndrome/2365512
- https://www.biospace.com/press-releases/jw-pharmaceutical-presents-preclinical-results-and-global-development-strategy-for-ddc-02-a-novel-therapeutic-candidate-for-rare-neurodevelopmental-disorders
- https://www.biospace.com/press-releases/precigen-gains-advantage-as-papzimeos-granted-orphan-drug-exclusivity-by-fda-long-term-data-from-clinical-study-encouraging
- https://www.businesswire.com/news/home/20260612407717/en/Rocket-Pharmaceuticals-Announces-Closing-of-Sale-of-Rare-Pediatric-Disease-Priority-Review-Voucher-for-%24180-Million